Daniele Sblattero
Daniele Sblattero
affiliation: Università del Piemonte Orientale
research area(s): Molecular Biology, Cancer Biology
Course: Biotechnologies For Human Health
University/Istitution: Università del Piemonte Orientale
- 1990-1995 University Degree in Biological Sciences, specialty Molecular Biology, University of Trieste (Italy).
- 1995-November 1999 Ph.D. program in Biophysics Sector at SISSA/ISAS, Trieste, Italy. Ph.D. degree with honours in Biophysics.
2005 – present, Associate Professor of Applied Biology, Faculty of Medicine, University of Eastern Piedmont, Novara. Italy
2001 – 2004 Research assistant, Department of Biology, University of Trieste.
1999 - 2000 Post Doctoral Fellowship, IRCCS "Burlo Garofolo" Trieste, Italy.
1999- 2000 Visiting scientist at the Center for Vaccine Development, University of Maryland at Baltimore, Baltimore USA.
1997 -1998 short term Technical consultant, Los Alamos National Laboratoriy, Life Science Division, Los Alamos, New Mexico, USA, project:

He has published over 55 papers on international journals and holds 3 patents in phage display technology.
His group has published over 30 paper on the application of the phage display technology for library construction, and selection for the isolation of recombinant antibodies from both naïve or autoimmune sources (celiac disease and T1DM)
Daniele Sblattero is associate professor at the Faculty of Medicine. He leads since 2005 the Laboratory of Applied Biology at the Department of Medical Sciences. He has been working on phage display and recombinant antibody technologies since 1994. The research activity of the lab is focused on the
development of novel technologies for improving phage display vectors for the generation of bigger and better libraries of both antibodies and antigens. Large naive antibodies libraries have been constructed trough an innovative in vivo recombination approach (EU patent EP1131421). This library had been used for the selection of therapeutic antibodies leading to the isolation of several
recombinant antibodies. These molecules have been approved as orphan drug by EMEA (patent EP1529063), are in preclinical evaluation (patent WO2006100679), or are in the advanced research
stage anti CD55 CD59 (USSN 12/919,816); Anti TRAIL_R2 and several other undisclosed target. The group has also extensive experience on research projects focused on the engineering of recombinant antibodies for improved in vitro and in vivo therapeutics performance of the isolated antibodies. Some of these are already in late preclinical studies. Furthermore during the last years
antibody libraries have been constructed from autoimmune patients for the characterization of the molecular mechanisms of the humoral response in autoimmune diseases, in particular Celiac Disease and Type 1 Diabetes.
Selected publications in the last 3 years

1. Caputo I, Barone MV, Lepretti M, Martucciello S, Nista I, Troncone R, Auricchio S, Sblattero D, Esposito C. Celiac anti-tissue transglutaminase antibodies interfere with the uptake of alpha gliadin peptide 31-43 but not of peptide 57-68 by epithelial cells. Biochim Biophys Acta. 2010 Sep;1802(9):717-27
2. Dianzani C, Minelli R, Mesturini R, Chiocchetti A, Barrera G, Boscolo S,Sarasso C, Gigliotti CL, Sblattero D, Yagi J, Rojo JM, Fantozzi R, Dianzani U. B7h triggering inhibits umbilical vascular endothelial cell adhesiveness to tumor cell lines and polymorphonuclear cells. J Immunol. 2010 Oct 1;185(7):3970-9
3. Di Niro R, Sulic AM, Mignone F, D'Angelo S, Bordoni R, Iacono M, Marzari R,Gaiotto T, Lavric M, Bradbury AR, Biancone L, Zevin-Sonkin D, De Bellis G,Santoro C, Sblattero D. Rapid interactome profiling by massive sequencing.Nucleic Acids Res. 2010 May;38(9):e110. Epub 2010 Feb 9.
4. Secchiero P, Sblattero D, Chiaruttini C, Melloni E, Macor P, Zorzet S, Tripodo C, Tedesco F, Marzari R, Zauli G. Selection and characterization of a novel agonistic human recombinant anti-TRAIL-R2 minibody with anti-leukemic activity. Int J Immunopathol Pharmacol. 2009 Jan-Mar;22(1):73-83.
5. Maglio M, Florian F, Vecchiet M, Auricchio R, Paparo F, Spadaro R, Zanzi D, Rapacciuolo L, Franzese A, Sblattero D, Marzari R, Troncone R. The great majority of children with type 1 diabetes produce and deposit anti-tissue Transglutaminase antibodies in the small intestine. Diabetes. 2009 Apr 28.
6. Radicke S, Cotella D, Sblattero D, Ravens U, Santoro C, Wettwer E. The transmembrane beta-subunits KCNE1, KCNE2, and DPP6 modify pharmacological effects of the antiarrhythmic agent tedisamil on the transient outward current Ito. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jun;379(6):617-26. Epub 2009 Jan 20.
7. Secco P, D'Agostini E, Marzari R, Licciulli M, Di Niro R, D'Angelo S, Bradbury AR, Dianzani U, Santoro C, Sblattero D. Antibody library selection by the -lactamase protein fragment complementation assay. Protein Eng Des Sel. 2009 Mar;22(3):149-58.
8. Boria I, Cotella D, Dianzani I, Santoro C, Sblattero D. Primer sets for cloning the human repertoire of T cell Receptor Variable regions. BMC Immunol. 2008 Aug 29;9:50.
9. Villanacci V, Not T, Sblattero D, Gaiotto T, Chirdo F, Galletti A, Bassotti G. Mucosal tissue transglutaminase expression in celiac disease. J Cell Mol Med. 2009 Feb;13(2):334-40.
10. Di Niro R, Sblattero D, Florian F, Stebel M, Zentilin L, Giacca M, Villanacci V, Galletti A, Not T, Ventura A, Marzari R. Anti-idiotypic response in mice expressing human autoantibodies. Mol Immunol. 2008 Mar;45(6):1782-91.
Project Title:
1 Ph D. position is available full time to work on innovative biomedical technologies in the framework of a Marie Curie Initial Training Networks (ITN) project.
TRANSPATH project will accelerate the development of new strategies for the treatment and diagnosis of human diseases related to the enzyme transglutaminase (TG), including metastatic cancer, neurodegeneration and celiac disease. The subject is highly relevant as deregulation of tissue transglutaminase activity is observed in a number of human diseases while the exact mechanisms are largely unknown. The project targets this unmet clinical need. New techniques and recent scientific advances make TRANSPATH extremely timely. The ITN will facilitate exchange of knowledge and technology between 7 leading European research teams in transglutaminases, 3 SME partners and 2 associate SMEs. The main objective is: to establish the molecular nature of the role of transglutaminases in the pathogenesis of diseases which are known to involve the multifunctional activity of these enzymes with a view to developing novel specific inhibitors and new therapeutic approaches which will have a major impact on their treatment.
Web page http://ec.europa.eu/research/mariecurieactions/

Project Title:
dissecting epitome at a glance
In recent years, we have developed an innovative technological platform that allows discovery of virtually all epitopes recognized by disease-associated autoimmune sera (referred as Autoimmunome). Comparative analyses of autoimmunomes will provide the groundwork to profile the autoimmune response in a wide set of diseases and will enable the construction of disease-specific �molecular fingerprinting�. The pipeline we have developed has the features to become a standard platform to identify multiple targets recognized by autoantibodies. Preliminary data show that this is a powerful method that allows a global analysis of the autoantibody repertoire in autoimmune diseases, and, we anticipate, in other diseases characterized by the presence of autoantibodies, such as cancer. The proposed project is based on multidisciplinary competencies that combine basic and applied research on autoimmunity to high-throughput genomic technologies and bioinformatics. It will involve complementary expertises from the Interdisciplinary Research Center of Autoimmune Diseases (IRCAD) at the University of Eastern Piedomont in Novara and the Insitute of Biomedical Technologies (ITB) of the National Research Council (CNR) in Milan. The project� pipeline is innovative and not yet reported by others and the expected results will be valuable for research and clinical purposes.

The specific aims of this project are:
i) to define disease-, or more generally, autoimmunity-associated molecular signatures through the analysis of the autoimmunomes;
ii) to settle public databases storing autoimmunome data and quality-proofed biological samples;
iii) to develop novel diagnostic tools to predict more effectively autoimmune disease onset and evolution;
This will be achieved through a two steps process. First, manufactured pilot protein-arrays, containing the prominent autoimmunome-derived antigens, will be tested with large sets of sera available in order to validate the different array platforms. Then, we will exploit novel device formats and substrates in order to increase their handling and performances [e.g.: point of care devices (POC)]. Array-based techniques will allow clinicians to acquire comprehensive panels of autoantibody profiles that could be integrated with clinical information and other biomarker